Accelerate the uptake and use of underused and new vaccines by strengthening country decision-making and introduction
The first 10 years of Gavi's work focused mainly on catalysing adoption of vaccines against yellow fever, hepatitis B (hepB) and Haemophilus influenzae type b (Hib).
In the next decade, Gavi will maintain momentum on these antigens but also target new vaccines, which hold the greatest potential to achieve progress on the Millennium Development Goals (MDG), in particular MDG 4 - the reduction of child mortality.
100 new vaccine introductions
Gavi's ambition is to accelerate the introduction of routine meningitis, pneumococcal and rotavirus vaccines and support campaigns against yellow fever and meningitis.
The Vaccine Alliance will also begin activities to prepare for other new vaccines, including human papillomavirus (HPV), Japanese encephalitis, typhoid and rubella.
If the Vaccine Alliance is fully resourced to meet demand, up to 100 new vaccine introductions across Gavi-eligible countries would occur during the second five-year strategy. The majority of these introductions are pneumococcal and rotavirus vaccines.